Kylonova (Xiamen) Biopharma Co., Ltd. is mainly engaged in the research and development of new drugs and delivery platforms for siRNA (small interfering nucleic acids). The company has established three delivery platforms for siRNA with proprietary technologies, including Nano-Lipid Particle(NPDP) , a Multi-Valent Import platform (MVIP) and Lipid-Coupling Delivery platform(LCDP). The technologies and quality standards of three delivery platforms are on the cutting-edge in the same fields, and can be scaled-up and manufactured for commercialization. Kylonova also performssolid phase oligonucleotide synthesis and DNA and RNA API production and can supply a contract manufacture.

Midatech Ltd. engages in research and experimental development on biotechnology services. The company is headquartered in Abingdon, the United Kingdom.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Sichuan Kelun Botai Biomedical Co., Ltd., established on 2016-11-22, Business scope includes biopharmaceuticals,Chemical Raw Materials,Research and development of chemical preparations,production and sales;Import and export,Technology Import and Export;Technical extension services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Beijing Sannuo Jiayi Biotechnology Co., Ltd., established on 2002-05-29, Business scope includes medical technology development,Technology Promotion,technology transfer,technical consulting,Technical Services,Technical Training.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Nippon Shinyaku Co., Ltd. engages in the manufacture and sale of pharmaceuticals and foodstuffs. Its operations are carried out through the Pharmaceuticals and Functional Food divisions. The Pharmaceuticals division develops and distributes drugs that treat urological diseases, inflammation, allergies, hematological malignancies, cardiovascular and metabolic diseases, and gastrointestinal disorders. The Functional Food division manufactures and supplies health food ingredients, preservatives, protein preparations, nutritional ingredients, seasonings and spices, and sterilization cleaning agents. The company was founded on November 20, 1911 and is headquartered Kyoto, Japan.

Suzhou Ribo Life Science Co. Ltd. is a leading siRNA drug development company. Ribo has built strength on various siRNA drug development platforms, including target discovery, siRNA design and screening, chemical modification, delivery technology, PD/PK study, safety evaluation, clinical trial, etc. Particularly, Ribo has explored and evaluated varieties of siRNA delivery systems, such as liposome, polymer, dendrimer, protein and peptide complex. The company was founded on January 1, 2007 and is headquartered in Kunshan, china.

Henan True Biotechnology Co., Ltd., established on 2012-09-12, Business scope includes research and development,Manufacture and sales of anticancer drugs,antiviral drugs,Drugs for treating diabetes-related diseases and drugs for cardiovascular and cerebrovascular diseases and aging-related diseases.Medical Raw Materials,medical tablet,soft,hard capsule,Granules,Powder,Research and Development of Biologics,production and sales;Research and development of biomedical technology,Consulting and Services;R&D of general chemical products,production and sales;Acting as an agent for the import, export and sales of various biomedical products(Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of).(legally approved projects,Business activities can only be carried out after approval by relevant departments).

Ai-biopharma develops drugs for the treatment of human diseases and medicinal chemistry services. They provides consulting on antiviral, nucleoside, nucleotides, prodrug targeting, and small molecule medicinal chemistry discovery. In addition they provide services such as computer aided drug design, chemoinformatic, database, 3D modeling, data analysis, optimization, SAR, and QSAR.

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.

Sentac Medical Technology (Shanghai) Co., Ltd., established on 2006-08-17, The business scope includes the use of targeted,Production and research and development of new dosage forms and new products of new technologies such as transdermal absorption,biology-Production and research and development of high-tech and new products of electronic medicine,Biomedical Materials and Products(remove human stem cells,Genetic Diagnosis and Therapy),Medical electronic equipment,Intervention equipment,Production and R&D of medical implant materials,Transfer of own achievements,Sell ​​self-produced products,And provide related technical consulting services(Involved in the production of medical devices,Business,Production and operation with a license).

Suzhou Liyuan Pharmaceutical Technology Co., Ltd., established on 2007-03-19, Business scope includes licensed business items:No general operating items:Pharmaceutical Research and Development,Technical Services and Consulting.

Gritpharma engaged in the industrialization of new pharmaceutical products, technology transfer, technical assistance, and the creation of new drugs. Complete business skills in areas like clinical research.

Kunming Institute of Precious Metals is a Chinese private company located in Kunming. The firm engages in scientific research institute that specializing in the development of precious metals.

nLife Therapeutics, S.L., a Granada, Spain-based company that develops innovative tratments for CNS diseases. The company intends to use the funds to advance clinical trials for its treatments. nLife Therapeutics is working on next generation targeted nucleic acids products. Its technology delivers conjugated nucleic acids with small chemicals to selected neurons after a single intra-nasal application.